Actively Recruiting
Comparison of Three PENG Block Versions Using 20 mL 0.2% Ropivacaine With Different Dexamethasone and Dexmedetomidine Combinations in Patients 65 Years and Older Undergoing Hip Surgery
Led by Poznan University of Medical Sciences · Updated on 2026-05-22
120
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are comparing three different versions of the Pericapsular Nerve Group (PENG) block in adults aged 65 years and older undergoing hip surgery. The PENG block is a regional anesthesia technique aimed at reducing pain and decreasing the use of strong opioid medications after surgery. The study seeks to find the best combination of medications added to the PENG block to improve pain relief, patient comfort, and recovery while evaluating safety and side effects. All participants will receive a PENG block with 20 mL of 0.2% ropivacaine. They will be randomly assigned to one of three groups: Group 1 receives ropivacaine plus 4 mg of dexamethasone intravenously; Group 2 receives ropivacaine with 25 micrograms of dexmedetomidine near the nerves plus 4 mg of dexamethasone intravenously; Group 3 receives ropivacaine with both 25 micrograms of dexmedetomidine and 4 mg of dexamethasone near the nerves. Some groups will receive placebos to keep the study blinded. Participants will be followed after surgery to assess pain levels using numerical rating scales at several intervals up to 48 hours, opioid use, side effects, nerve block duration, motor function, time to first rescue analgesia, and patient satisfaction. Safety will be monitored through recording adverse events and neurological complications. The study aims to identify the most effective PENG block variant to improve pain management and support faster recovery after hip surgery in older adults.
CONDITIONS
Brief Title
PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 years or older
- Scheduled for elective or emergency hip surgery such as hip fracture fixation or hip arthroplasty
- ASA physical status I to III
- Able to communicate pain intensity using a numerical rating scale
- Provided written informed consent or consent from legal representative
- Planned use of PENG block as part of multimodal perioperative pain management
You will not qualify if you...
- Refusal or inability to give informed consent
- Allergy or intolerance to ropivacaine, dexamethasone, or dexmedetomidine
- Existing neurological deficit or neuropathy in the affected limb
- Blood clotting issues (INR >1.5, low platelets) or anticoagulation contraindicating regional anesthesia
- Infection near the injection site
- Severe liver or kidney problems
- History of daily opioid use over 30 days before surgery
- Cognitive impairment or delirium preventing reliable pain assessment
- Body mass index over 40 kg/m²
- Receiving another regional nerve block for hip surgery
- Pregnancy or breastfeeding
- Participation in another interventional clinical trial within the last 30 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Surgery day and up to 48 hours after surgery
Participants receive a PENG block with 20 mL of 0.2% ropivacaine combined with different dexamethasone and dexmedetomidine medication regimens to manage pain during hip surgery.
1 treatment visit during surgery and assessments at 4, 8, 12, 24, and 48 hours after surgery
Duration - Up to 30 days after surgery
Participants are followed up to monitor pain levels, opioid use, side effects, motor function, and any complications up to hospital discharge and 30 days after surgery.
Several visits or contacts depending on hospital stay and follow-up schedule
Trial Site Locations
Total: 1 location
1
Poznan University of Medical Sciences
Poznan, Poland, 62-701
Actively Recruiting
Research Team
M
Malgorzata Reysner, MD PhD
M
Mslgorzata Reysner, MD PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here